Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved ...
CSR Wire

Medtronic Study of Investigational Nellcor™ Pulse Oximetry Technology Demonstrates Positive Results Across a Full Range of Skin Tones

January 22, 2026 /3BL/ – Medtronic, a global leader in healthcare technology, announced verification study results for its investigational Nellcor™ pulse oximetry with Nell-EQ™ intelligent processor ...